Beijing Strong Biotechnologies, Inc.
Shenzhen Stock ExchangeTotal Valuation
Beijing Strong Biotechnologies, Inc. carries a market capitalization of 6.65B, placing it among publicly traded companies globally. Its enterprise value stands at 8.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 6.65B |
| Enterprise Value | 8.69B |
Share Statistics
Beijing Strong Biotechnologies, Inc. currently has 588.33M shares outstanding.
| Shares Outstanding | 588.33M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Beijing Strong Biotechnologies, Inc. trades at a trailing price-to-earnings ratio of 18.39. The price-to-sales ratio is 5.59, and the price-to-book ratio stands at 2.54.
| PE Ratio | 18.39 |
| PS Ratio | 5.59 |
| PB Ratio | 2.54 |
| P/TBV Ratio | 3.59 |
| P/FCF Ratio | 198.04 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Beijing Strong Biotechnologies, Inc. trades at an EV/EBITDA multiple of 15.51 and an EV/FCF ratio of 102.26. The EV/Sales ratio of 5.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 15.51 provides insight into valuation relative to core operating earnings.
| EV / Sales | 5.78 |
| EV / EBITDA | 15.51 |
| EV / EBIT | 15.51 |
| EV / FCF | 102.26 |
Financial Position
Beijing Strong Biotechnologies, Inc. maintains a current ratio of 11.73, meaning it holds 11.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 28.56, indicating elevated leverage, while an interest coverage ratio of 11.67 demonstrates strong ability to service its debt obligations.
| Current Ratio | 11.73 |
| Quick Ratio | 4.21 |
| Debt / Equity | 28.56 |
| Debt / EBITDA | 2.07 |
| Interest Coverage | 11.67 |
Financial Efficiency
Beijing Strong Biotechnologies, Inc. posts a return on equity of 14.25 and a return on invested capital of 9.75.
| Return on Equity (ROE) | 14.25 |
| Return on Assets (ROA) | 8.52 |
| Return on Invested Capital (ROIC) | 9.75 |
| Return on Capital Employed (ROCE) | 11.46 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.37 |
Taxes
Over the trailing twelve months, Beijing Strong Biotechnologies, Inc. has paid 59.21M in income taxes, reflecting an effective tax rate of 11.46.
| Income Tax | 59.21M |
| Effective Tax Rate | 11.46 |
Stock Price Statistics
Beijing Strong Biotechnologies, Inc.'s stock has declined approximately -18.34532% over the past 52 weeks. The 50-day moving average sits at 12.15, while the 200-day moving average is 12.89.
| Beta (5Y) | N/A |
| 52-Week Price Change | -18.34532% |
| 50-Day Moving Average | 12.15 |
| 200-Day Moving Average | 12.89 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Beijing Strong Biotechnologies, Inc. generated 1.51B in revenue and converted that into 457.50M in net income, yielding earnings per share of 0.77. EBITDA reached 560.66M, while operating income came in at 560.66M.
| Revenue | 1.51B |
| Gross Profit | 1.20B |
| Operating Income | 560.66M |
| Pretax Income | 516.50M |
| Net Income | 457.50M |
| EBITDA | 560.66M |
| EBIT | 560.66M |
| Earnings Per Share (EPS) | 0.77 |
Balance Sheet
Beijing Strong Biotechnologies, Inc. holds 878.34M in cash and equivalents against 1.16B in total debt, resulting in a net debt position of 245.11M. Total book value stands at 3.32B, with working capital of 2.24B providing operational flexibility.
| Cash & Cash Equivalents | 878.34M |
| Total Debt | 1.16B |
| Net Debt | 245.11M |
| Equity (Book Value) | 3.32B |
| Book Value Per Share | 5.58 |
| Working Capital | 2.24B |
Cash Flow
After subtracting -42.49M in capital expenditures, free cash flow totaled -42.49M - equivalent to -0.07 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -42.49M |
| Free Cash Flow | -42.49M |
| FCF Per Share | -0.07 |
Margins
Beijing Strong Biotechnologies, Inc. operates with a gross margin of 79.62, reflecting its pricing power and cost economics. The operating margin of 37.24 and net profit margin of 30.39 provide insight into operational efficiency.
| Gross Margin | 79.62 |
| Operating Margin | 37.24 |
| Pretax Margin | 34.31 |
| Profit Margin | 30.39 |
| EBITDA Margin | 37.24 |
Dividends & Yields
The company's payout ratio of 53.82 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.41 |
| Dividend Yield | N/A |
| Payout Ratio | 53.82 |
| Shareholder Yield | 3.83 |
| FCF Yield | 0.50 |
Stock Splits
Beijing Strong Biotechnologies, Inc.'s most recent stock split took place on May 3, 2016 with a 1:2 split ratio.
| Last Split Date | 5/3/2016 |
| Split Ratio | 1:2 |
Scores
Beijing Strong Biotechnologies, Inc. posts an Altman Z-Score of 6.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.34 |